SSY Group Signs LOI with Longhai Pharma to Acquire Rights for Four Biosimilars

Bulletin Express06-05

On 5 June 2026, SSY Group’s wholly owned subsidiary Shijiazhuang No. 4 Pharmaceutical Co., Ltd. entered into a 90-day exclusive letter of intent with Hebei Longhai Pharmaceutical Co., Ltd. for a potential transfer of four biosimilar drug assets—ustekinumab, dupilumab, aflibercept injection and evolocumab.

Under the proposed terms, Longhai Pharma will complete all remaining research materials and fully transfer technical know-how, patents (including application rights), registration dossiers and exclusive commercial interests to Shijiazhuang No. 4. Upon execution of a definitive agreement and receipt of a down payment, market authorisation holder status and all related intellectual-property rights would vest solely in Shijiazhuang No. 4, while Longhai Pharma would retain eligibility for agreed milestone payments.

The LOI grants SSY Group an exclusivity window of 90 days, during which Longhai Pharma is prohibited from negotiating similar transactions with third parties. SSY Group will conduct technical, legal and financial due diligence before finalising a formal transfer agreement.

Management expects that, if completed, the transaction will strengthen SSY Group’s biologics pipeline and support future growth by securing exclusive rights to the four biosimilars. The parties have not yet executed a definitive contract, and the project may or may not proceed. Investors are advised to exercise caution when dealing in SSY Group shares.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1128222216?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-05 12:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1128222216","market":"us","top_or_hot":-1,"title":"SSY Group Signs LOI with Longhai Pharma to Acquire Rights for Four Biosimilars","media":"Bulletin Express","content":"<p>On 5 June 2026, SSY Group’s wholly owned subsidiary Shijiazhuang No. 4 Pharmaceutical Co., Ltd. entered into a 90-day exclusive letter of intent with Hebei Longhai Pharmaceutical Co., Ltd. for a potential transfer of four biosimilar drug assets—ustekinumab, dupilumab, aflibercept injection and evolocumab.</p>\n<p>Under the proposed terms, Longhai Pharma will complete all remaining research materials and fully transfer technical know-how, patents (including application rights), registration dossiers and exclusive commercial interests to Shijiazhuang No. 4. Upon execution of a definitive agreement and receipt of a down payment, market authorisation holder status and all related intellectual-property rights would vest solely in Shijiazhuang No. 4, while Longhai Pharma would retain eligibility for agreed milestone payments.</p>\n<p>The LOI grants SSY Group an exclusivity window of 90 days, during which Longhai Pharma is prohibited from negotiating similar transactions with third parties. SSY Group will conduct technical, legal and financial due diligence before finalising a formal transfer agreement.</p>\n<p>Management expects that, if completed, the transaction will strengthen SSY Group’s biologics pipeline and support future growth by securing exclusive rights to the four biosimilars. The parties have not yet executed a definitive contract, and the project may or may not proceed. Investors are advised to exercise caution when dealing in SSY Group shares.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SSY Group Signs LOI with Longhai Pharma to Acquire Rights for Four Biosimilars</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSSY Group Signs LOI with Longhai Pharma to Acquire Rights for Four Biosimilars\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-05 12:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>On 5 June 2026, SSY Group’s wholly owned subsidiary Shijiazhuang No. 4 Pharmaceutical Co., Ltd. entered into a 90-day exclusive letter of intent with Hebei Longhai Pharmaceutical Co., Ltd. for a potential transfer of four biosimilar drug assets—ustekinumab, dupilumab, aflibercept injection and evolocumab.</p>\n<p>Under the proposed terms, Longhai Pharma will complete all remaining research materials and fully transfer technical know-how, patents (including application rights), registration dossiers and exclusive commercial interests to Shijiazhuang No. 4. Upon execution of a definitive agreement and receipt of a down payment, market authorisation holder status and all related intellectual-property rights would vest solely in Shijiazhuang No. 4, while Longhai Pharma would retain eligibility for agreed milestone payments.</p>\n<p>The LOI grants SSY Group an exclusivity window of 90 days, during which Longhai Pharma is prohibited from negotiating similar transactions with third parties. SSY Group will conduct technical, legal and financial due diligence before finalising a formal transfer agreement.</p>\n<p>Management expects that, if completed, the transaction will strengthen SSY Group’s biologics pipeline and support future growth by securing exclusive rights to the four biosimilars. The parties have not yet executed a definitive contract, and the project may or may not proceed. Investors are advised to exercise caution when dealing in SSY Group shares.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02005","symbol_name":"石四药集团","start_time":0,"source_url":"","article_id":"1128222216","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1128222216","pubTimestamp":1780633382,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"On 5 June 2026, SSY Group’s wholly owned subsidiary Shijiazhuang No. 4 Pharmaceutical Co., Ltd. entered into a 90-day exclusive letter of intent with Hebei Longhai Pharmaceutical Co., Ltd. for a...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02005":"石四药集团"},"translate_title":"SSY集团与龙海制药签署意向书，收购四种生物仿制药的权利","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02005":1},"content_text":"On 5 June 2026, SSY Group’s wholly owned subsidiary Shijiazhuang No. 4 Pharmaceutical Co., Ltd. entered into a 90-day exclusive letter of intent with Hebei Longhai Pharmaceutical Co., Ltd. for a potential transfer of four biosimilar drug assets—ustekinumab, dupilumab, aflibercept injection and evolocumab.\nUnder the proposed terms, Longhai Pharma will complete all remaining research materials and fully transfer technical know-how, patents (including application rights), registration dossiers and exclusive commercial interests to Shijiazhuang No. 4. Upon execution of a definitive agreement and receipt of a down payment, market authorisation holder status and all related intellectual-property rights would vest solely in Shijiazhuang No. 4, while Longhai Pharma would retain eligibility for agreed milestone payments.\nThe LOI grants SSY Group an exclusivity window of 90 days, during which Longhai Pharma is prohibited from negotiating similar transactions with third parties. SSY Group will conduct technical, legal and financial due diligence before finalising a formal transfer agreement.\nManagement expects that, if completed, the transaction will strengthen SSY Group’s biologics pipeline and support future growth by securing exclusive rights to the four biosimilars. The parties have not yet executed a definitive contract, and the project may or may not proceed. Investors are advised to exercise caution when dealing in SSY Group shares.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1128222216","isCrawlerRequest":true}